Is Inhibikase Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Inhibikase Therapeutics Inc (IKT) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Inhibikase Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Inhibikase Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Inhibikase Therapeutics Inc?

Muslim investors may consider investing in Inhibikase Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Inhibikase Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Inhibikase Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Inhibikase Therapeutics Inc updated?

The Shariah compliance status of Inhibikase Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Inhibikase Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Inhibikase Therapeutics Inc?

You can check the latest Shariah compliance status of Inhibikase Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IKT Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 01, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Inhibikase Therapeutics Inc (IKT)

Based on 11 analysts giving stock ratings to Inhibikase Therapeutics Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Inhibikase Therapeutics Inc. Stock Analysis IKT

United States Health Care Micro Cap Report: 2025 Annual

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Key Statistics of Inhibikase Therapeutics Inc (IKT)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.72$1.84

Today's Open

$1.84

Volume

947.90K

P/E Ratio (TTM)

52 Week Range

$1.33$2.26

Market Cap

254.82M

Avg. Volume

878.60K

Dividend Yield

Financial Metrics & Statements of Inhibikase Therapeutics Inc (IKT)

FAQ's for Inhibikase Therapeutics Inc (IKT)

According to Musaffa’s Shariah screening methodology, Inhibikase Therapeutics Inc (IKT) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.